ABSIHealthcare · BiotechnologyThe 11 Wall Street analysts covering Absci Corp. hold a median 12-month price target of $16 — +77.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 14 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Absci Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Quality (20): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ABSI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +77.3% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $16 |
| 12 Oct 2026 | JP Morgan | Maintains | Overweight | $14 → $15 |
| 23 Sept 2026 | Needham | Reiterates | Buy | $11 |
| 9 Sept 2026 | LifeSci Capital | Initiates | Outperform | — |
| 8 Sept 2026 | BTIG | Maintains | Buy | — |
| 8 Sept 2026 | BTIG | Maintains | Buy | $13 → $16 |
| 12 Aug 2026 | BTIG | Reiterates | Buy | $13 |
| 12 Aug 2026 | BTIG | Reiterates | Buy | — |
| 12 Aug 2026 | Needham | Reiterates | Buy | $11 |
| 12 Aug 2026 | Needham | Reiterates | Buy | — |
| 2 July 2026 | Truist Securities | Maintains | Buy | — |
| 2 July 2026 | Truist Securities | Maintains | Buy | $11 → $17 |
| 25 June 2026 | HC Wainwright & Co. | Maintains | Buy | $8.00 → $16 |
| 25 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 June 2026 | BTIG | Maintains | Buy | — |
| 24 June 2026 | Needham | Reiterates | Buy | — |
| 15 June 2026 | Guggenheim | Maintains | Buy | — |
| 4 June 2026 | Leerink Partners | Initiates | Outperform | — |
| 28 May 2026 | BTIG | Initiates | Buy | — |
| 8 May 2026 | Truist Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABSI appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Absci Corp. returned +124.1% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 94% of US stocks
Cheaper than 1% of US stocks
Cheaper than 15% of US stocks
Cheaper than 86% of US stocks
Higher than 6% of US stocks
Higher than 11% of US stocks
Higher than 2% of US stocks
Higher than 30% of US stocks
Higher than 20% of US stocks
Higher than 12% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Absci Corp. has a market value of $1.6B and an enterprise value of $1.4B.
Revenue in the twelve months to 30 June 2026: $1.6M. The latest quarter shrank 46.4% year on year.
Net income over the same four quarters: −$121.1M, a −7756.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.80.
Free cash flow in the twelve months to 30 June 2026: −$109.0M.
Trailing P/E: −10.8×; forward P/E: −13.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Absci Corp. employs 140 people — $11K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Absci Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Absci announced that it will report business updates and third-quarter 2026 financial and operating results before market open on November 12, 2026.
Why it matters — ABSI watchers can note the scheduled date for the company’s next quarterly results and business update.
Absci announced preliminary details for its Phase 2 STORYLINE trial of ABS-201, its AI-designed antibody for endometriosis. The trial will assess efficacy and safety in patients with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain, with initiation anticipated in mid-2027.
Why it matters — This provides an early outlook on the clinical advancement of ABSI's lead AI-designed antibody candidate, indicating progress toward a large-market indication.
Absci Corporation presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The item reports on the company's participation and availability of the presentation transcript.
Why it matters — A transcript of Absci's presentation at a major healthcare conference gives ABSI watchers insight into the company's updates and positioning as shared with the investment community.
Absci Corporation was upgraded to "Buy" following positive interim Phase 1 data for ABS-201 in androgenetic alopecia (AGA). The therapy demonstrated an excellent pharmacokinetic profile enabling infrequent dosing (2-3 injections per 6 months) and strong safety/tolerability in single ascending dose cohorts. Upcoming catalysts include 13-week interim proof-of-concept data in the second half of 2026 and 26-week topline results in early 2027 for ABS-201 in AGA.
Why it matters — Absi watchers would care because the publication's upgrade reflects encouraging early clinical data for ABS-201 and points to several near-term readouts that could shape the company's outlook for its androgenetic alopecia program.
Absci Corp. announced that it will participate in upcoming investor conferences, with the announcement originating from Vancouver, Washington and New York. The company will present at these scheduled events.
Why it matters — Investors following ABSI may be interested to learn about the company's scheduled conference participation, which provides an opportunity to hear directly from management.
The 11 Wall Street analysts covering Absci Corp. have a median 12-month price target of $16, with estimates ranging from $10 to $17. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Absci Corp., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Absci Corp. 36 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Absci Corp. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +77.3% from the last close, and Ticker Nerd's factor model ranks Absci Corp. 36 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Absci Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $17 over the next 12 months.
Absci Corp. returned +124.1% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Absci Corporation is a clinical-stage biopharmaceutical company focused on discovering and designing protein-based therapeutics using generative artificial intelligence and synthetic biology. Absci integrates AI-driven modeling with high-throughput wet lab capabilities to create antibody and other biologic candidates for complex disease areas.
The most recent item we track (GlobeNewsWire, 13 Oct 2026): "Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026". Absci announced that it will report business updates and third-quarter 2026 financial and operating results before market open on November 12, 2026.
Absci Corporation is a clinical-stage biopharmaceutical company focused on discovering and designing protein-based therapeutics using generative artificial intelligence and synthetic biology. Absci integrates AI-driven modeling with high-throughput wet lab capabilities to create antibody and other biologic candidates for complex disease areas. Its current pipeline spans programs in immunology, oncology, inflammatory disease, and dermatology, reflecting a platform approach to drug creation rather than a single-product model. The company also collaborates with pharmaceutical and biotechnology partners to support therapeutic discovery and development efforts. Headquartered in Vancouver, Washington, Absci plays a role in the growing market for AI-enabled drug discovery, where data science and biological engineering are combined to improve how new medicines are identified and optimized.
CEO Mr. Sean McClain · 140 employees · United States · https://www.absci.com
